论文部分内容阅读
美国糖尿病协会(ADA)与欧洲糖尿病研究协会(EASD)共同新推出的2型糖尿病(T2DM)治疗指南中,推荐糖尿患者一旦确诊,应在生活方式干预同时服用二甲双胍。一些临床观察表明,在血糖水平较低时就开始服用二甲双胍,治疗有效而且持久,但这些研究中糖尿病病程(延迟治疗)不预示失效时间。据作者所知还没有研究用糖化血红蛋白(HbA_1c)=7%作为达标值比较二甲双胍即刻起用和晚用的差异。尽管在临床试验中二甲双胍的年失效率达4%,但临床应用中的实际失效率尚无报道。因此本文作者想通过在非研究设定但证明曾用二甲双胍成功降低HbA_1c<7%人
The Diabetes Association of America (ADA) and European Association for the Study of Diabetes (EASD) co-sponsored the New Type 2 Diabetes Guideline (T2DM), recommended that diabetics, once diagnosed, should be given metformin at the same time as lifestyle interventions. Some clinical observations indicate that metformin is started when blood glucose levels are low, and that treatment is effective and long lasting, but the duration of diabetes (delayed treatment) in these studies did not predict the duration of the failure. To the best of our knowledge, no studies have compared the immediate and late use of metformin with glycosylated hemoglobin (HbA 1 c) = 7% as the standard. Although metformin has an annual failure rate of 4% in clinical trials, the actual failure rate in clinical practice has not been reported. Therefore, the authors of the present study sought to reduce <7% HbA1c by successfully setting metformin in non-study settings